Both intravenous racemic ketamine and intranasal esketamine are currently used in various models of care for treatment-resistant depression (TRD) due to meta-analytic evidence of their antidepressant effects and the high demand for novel treatments.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (2)

• treatment-resistant depression concept
• esketamine concept